A well-funded Baltimore startup whose spray cryotechnology flash-freezes unwanted or malignant tissues inside the body just raised a touch more capital.
According to a regulatory filing, CSA Medical just raised $2.9 million – on top of the $55 million it’s raised to date. Before this, CSA Medical’s most recent fundraise was a $16 million Series C in 2013. Previous investors include Ascension Ventures, SV Life Sciences, Intersouth Partners, First Analysis, Rose Park Advisors and Blue Heron Capital.
CSA Medical’s spray cryotherapy devices have actually been FDA-cleared and on the market since 2007, in use for endoscopic ablation. But it recently developed a new system, called truFreeze, that delivers frigid liquid nitrogen through a small catheter to selectively destroy cells, while keeping the underlying collagen tissue structure preserved as a scaffold for heathy tissue to regrow. Here’s how it works:
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.